Brazil

Brazil's primary health regulatory authority is the Agência Nacional de Vigilância Sanitária (ANVISA), established under Law No. 9.782/1999. ANVISA oversees the registration and post-market surveillance of pharmaceuticals, medical devices, in vitro diagnostics, and digital health solutions. The general approval process requires submission of a registration dossier (petição de registro) through ANVISA's electronic platform, Solicita, followed by technical review across relevant directorates. Risk-based classification determines the review pathway: lower-risk products may qualify for expedited or notification-based routes, while higher-risk or novel products undergo full technical analysis. ANVISA also operates priority review mechanisms (análise prioritária) for products addressing unmet medical needs, rare diseases, or public health emergencies, which can substantially reduce timelines.

All foreign manufacturers seeking Brazilian registration must appoint a local Legal Representative (Responsável Técnico) and a Brazilian-domiciled regulatory holder (detentora do registro). Dossiers are generally required to follow CTD (Common Technical Document) formatting, and ANVISA has progressively aligned its requirements with ICH guidelines, particularly for pharmaceuticals. For medical devices and diagnostics, technical documentation must demonstrate conformity with applicable ABNT or internationally recognized standards. Notably, ANVISA has implemented Resolution RDC 204/2017 and subsequent normative instructions to modernize device regulation, and the PERT (Programa Especial de Regularização Tributária) exemptions framework has been updated to streamline post-approval variations. Recent reforms under the Economic Freedom Law (Law No. 13.874/2019) introduced automatic approval mechanisms for products already registered in stringent regulatory authorities (SRAs) such as the FDA, EMA, Health Canada, and TGA, significantly accelerating timelines for eligible products.

Brazil's public health procurement operates through a layered federal and subnational structure. At the federal level, the Ministério da Saúde (Ministry of Health) coordinates centralized purchasing for strategic health products, including vaccines, essential medicines, and high-cost therapies, largely through the Departamento de Assistência Farmacêutica e Insumos Estratégicos (DAF) and the Departamento de Logística em Saúde (DLOG). National tenders are conducted via the federal government's procurement portal (Comprasnet, transitioning to the PNCP platform) under Law No. 14.133/2021, which replaced the former Lei de Licitações (Law No. 8.666/1993). The Sistema Único de Saúde (SUS) serves as the backbone of public procurement, with the federal government responsible for centralized purchases of specialized and high-cost products, while states and municipalities procure products for primary and secondary care through their own secretariats. Atas de Registro de Preços (price registration records) and Pregão Eletrônico (electronic reverse auctions) are the most common procurement instruments, and CMED (Câmara de Regulação do Mercado de Medicamentos) price ceilings apply to all pharmaceutical transactions within the SUS.

The private sector represents a substantial share of health product consumption in Brazil, channeled through hospital networks, pharmacy chains, health maintenance organizations (operadoras de planos de saúde) regulated by the Agência Nacional de Saúde Suplementar (ANS), and independent distributors. Donor-funded procurement channels such as UNICEF, the Global Fund, and PAHO/OPAS play a more limited role compared to lower-income markets, though PAHO's Strategic Fund has historically been used to procure vaccines and certain medicines on behalf of the Brazilian government at preferential prices. Brazil maintains explicit local manufacturing preference policies: the Lei de Conteúdo Local and the Complexo Econômico-Industrial da Saúde (CEIS) strategy promote domestic production through Produtividade para o Desenvolvimento (PDP) partnerships, which are formal technology-transfer agreements between foreign innovators and Brazilian public or private manufacturers, granting preferential SUS purchasing rights to domestically produced products. These PDPs are a critical market access consideration for multinational companies seeking long-term public sector positioning in Brazil.